drugset / Trial / NCT03254654
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Timeline
- Start
- 2017-08-16
- Primary completion
- 2021-08-01
- Completion
- 2021-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | Vinorelbine | Small molecule | 20 mg/m2 | — |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | — |